Dottikon Es Holding AG
SIX:DESN

Watchlist Manager
Dottikon Es Holding AG Logo
Dottikon Es Holding AG
SIX:DESN
Watchlist
Price: 216.5 CHF Market Closed
Market Cap: 3B CHF
Have any thoughts about
Dottikon Es Holding AG?
Write Note

Dottikon Es Holding AG
Operating Expenses

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Dottikon Es Holding AG
Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
Dottikon Es Holding AG
SIX:DESN
Operating Expenses
-CHf132.1m
CAGR 3-Years
-3%
CAGR 5-Years
-5%
CAGR 10-Years
-6%
Sika AG
F:SIKA
Operating Expenses
-CHf4.4B
CAGR 3-Years
-11%
CAGR 5-Years
-9%
CAGR 10-Years
-7%
C
Clariant AG
SIX:CLN
Operating Expenses
-CHf829m
CAGR 3-Years
1%
CAGR 5-Years
-2%
CAGR 10-Years
N/A
Givaudan SA
SIX:GIVN
Operating Expenses
-CHf1.8B
CAGR 3-Years
-2%
CAGR 5-Years
-3%
CAGR 10-Years
-3%
Ems Chemie Holding AG
SIX:EMSN
Operating Expenses
-CHf1.6B
CAGR 3-Years
-2%
CAGR 5-Years
1%
CAGR 10-Years
0%
D
DSM-Firmenich AG
AEX:DSFIR
Operating Expenses
-€3.1B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Dottikon Es Holding AG
Glance View

Market Cap
3B CHF
Industry
Chemicals

Dottikon Es Holding AG stands as one of Switzerland's understated gems in the realm of fine chemicals and pharmaceuticals. Born from Switzerland's rich tradition of precision and quality, the company operates primarily in the realm of exclusive synthesis, tailored to meet the stringent demands of the pharmaceuticals industry. At its core, Dottikon specializes in hazardous chemical reactions, priding itself on an ability to transform complex chemical processes into high-quality results. This specialization provides a competitive edge, allowing Dottikon to focus on developing innovative and complex molecules which serve as active pharmaceutical ingredients (APIs). It's a business model that not only underscores the company's technical expertise but also its commitment to safety and environmental stewardship, given the heightened risks associated with hazardous materials. Revenue for Dottikon is chiefly generated from strategic partnerships with major pharmaceutical companies. By offering a unique combination of research and development capabilities coupled with state-of-the-art production facilities, Dottikon caters to bespoke needs, from initial developmental scales to full-fledged commercial production runs. The trust and collaboration between Dottikon and its clients are pivotal, as the company becomes an indispensable partner in the clients’ supply chain. As the pharmaceutical sector continues to evolve and demand for specialized molecules increases, Dottikon’s focus on exclusivity and expertise positions it well within the industry, ensuring steady demand and solidifying its role as a reliable, albeit lesser-known, catalyst in advancing pharmaceutical innovations.

DESN Intrinsic Value
163.42 CHF
Overvaluation 25%
Intrinsic Value
Price

See Also

What is Dottikon Es Holding AG's Operating Expenses?
Operating Expenses
-132.1m CHF

Based on the financial report for Sep 30, 2024, Dottikon Es Holding AG's Operating Expenses amounts to -132.1m CHF.

What is Dottikon Es Holding AG's Operating Expenses growth rate?
Operating Expenses CAGR 10Y
-6%

Over the last year, the Operating Expenses growth was -4%. The average annual Operating Expenses growth rates for Dottikon Es Holding AG have been -3% over the past three years , -5% over the past five years , and -6% over the past ten years .

Back to Top